HLA

Global HLA Typing for Transplants Market Expected to Reach $1.1 Billion by 2028, Driven by Technological Advancements and Rising Transplant Demand

Retrieved on: 
Mercoledì, Novembre 1, 2023
Laboratory, Antibody, Government, Biotechnology, Region, PCR, Research, SSO, Instrument, Real, NGS, SSP, Hospital, Transplant, USD, Organ, HLA, Speciality chemicals, Software

The global HLA typing for the transplants market is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%.

Key Points: 
  • The global HLA typing for the transplants market is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%.
  • Rising technological advancements in the field of HLA typing, increasing demand for transplantation, rising initiatives by the government to boost organ donation, and increasing research activities in the field of HLA typing to support the market growth.
  • The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2022.
  • In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market.

Medigene Reports Financial Results and Corporate Update for Q3 2023

Retrieved on: 
Giovedì, Ottobre 26, 2023
Acceleration, IND, Patent, Innovation, ESMO, Logitech Driving Force GT, BioNTech, TCR, Platform, Congress, European Society for Medical Oncology, Intellectual property, KRAS, R, European Patent Office, Annual report, Kirsten, Partnership, CD28, EUR, Oncology, FSE, Senior, Therapy, European Patent Convention, IP, Patient, HLA, Frontiers, Rare-earth element, Pharmaceutical industry, Vaccine

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results and provided a corporate update for the third quarter of 2023.

Key Points: 
  • Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results and provided a corporate update for the third quarter of 2023.
  • The Company’s Quarterly Statement Q3 2023 is available on Medigene’s website: https://medigene.com/investors-media/reports-presentations/
    “In the past quarter, we continued to successfully execute our corporate strategy and deliver on our commitments.
  • The Executive Management Board, therefore, maintains its guidance for the fiscal year 2023 published in the annual report 2022 on March 29, 2023, in its entirety.
  • Subsequent to the quarter, first pre-clinical data on MDG2011 was presented at the European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid in October 2023.

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

Retrieved on: 
Lunedì, Ottobre 23, 2023
Bispecific monoclonal antibody, The Cancer Genome Atlas, Adenocarcinoma, TCGA, TCE, NSCLC, ESMO, IHC, HPV, Data, Head, Bladder cancer, Neck, Neoplasm, Histology, Messenger, Bivalent, Patient, HLA, Vaccine

ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Key Points: 
  • The key objective of this study was for CDR-Life to explore MAGE-A4 expression levels in solid tumors using The Cancer Genome Atlas (TCGA) mRNA dataset.
  • In addition, subgroups of high MAGE-A4 expression were present across a wide range of solid cancers including lung adenocarcinoma, ovarian and gastric cancers.
  • “CDR404 is a novel, bispecific and bivalent T-cell engager differentiated from previous solid tumor T-cell engagers targeting MAGE-A4 in the clinic.
  • The MAGE-A4 mRNA distribution profiles across multiple tumor types indicate, that a tumor MAGE-A4 assay will be indispensable for trial screening.

Health Literacy Innovations (HLI) Announces A Free AI/Health Literacy Webinar October 30th

Retrieved on: 
Martedì, Ottobre 24, 2023
EST, Literacy, AI, Health literacy, HLA, Confusion, HLI, Medical device

BETHESDA, Md., Oct. 24, 2023 /PRNewswire-PRWeb/ -- To help the health care industry better understand how AI can enhance health literacy, Health Literacy Innovations (HLI), a health literacy company that creates tools to help eliminate medical mistakes and confusion from low health literacy, today announces a free AI/health literacy webinar October 30th, 3:00 pm EST.

Key Points: 
  • Can AI help to conquer low health literacy?
  • BETHESDA, Md., Oct. 24, 2023 /PRNewswire-PRWeb/ -- To help the health care industry better understand how AI can enhance health literacy, Health Literacy Innovations (HLI), a health literacy company that creates tools to help eliminate medical mistakes and confusion from low health literacy, today announces a free AI/health literacy webinar October 30th, 3:00 pm EST.
  • "Our goal is to bring health communicators and those interested in AI as a tool to conquer health literacy, together"
    "As AI grows within health care, there is a lot to be uncovered about AI's place and potential in health literacy," says HLA Chief Content Expert and Multilingual Director Aracely Rosales.
  • "Our goal is to bring health communicators and those interested in AI as a tool to conquer health literacy, together," says Rosales.

ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity Based on T-Cell Phenotypes in New Peer-Reviewed Research

Retrieved on: 
Giovedì, Ottobre 19, 2023
Research, General Health, Pharmaceutical, Oncology, Technology, Genetics, Health Technology, Science, Biotechnology, Other Technology, Other Science, Health, Therapy, SARS-CoV-2, RNA, Antigen, TCR, Allele, COVID-19, Machine learning, CMV, Cancer, EBV, Patient, Cell Reports, HLA, Vaccine, Medical imaging

The research could have profound implications for the use of machine learning in the discovery and development of T-cell based immunotherapies.

Key Points: 
  • The research could have profound implications for the use of machine learning in the discovery and development of T-cell based immunotherapies.
  • Machine learning models trained on immune profile features of virus-specific cells were built to predict viral T-cell specificity.
  • Machine learning was used to predict antigen specificity from T-cell phenotypes.
  • Machine learning can be used as a statistically rigorous and unbiased method to accurately predict antigen specificity based on T-cell phenotype information.

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Martedì, Ottobre 17, 2023
Science, Biotechnology, Research, Surgery, Health, Health Technology, Genetics, Clinical Trials, Standard of care, Abstract, Paris Institute of Statistics, Society, Laboratory for Experimental Medicine and Surgery in Primates, Parameter, University of Utah, NGS, Assistant, HLA, LIMS, Standard, Caregiver, University, Histocompatibility, Laboratory information management system, St Paul's Cathedral, Chimera, Doctor of Philosophy, ACHI, Kidney transplantation, Biomarker, Laboratory, Patient, Management, Dentistry, Transplant, Nephrology, MD, Immunogenetics, Medicine

These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.

Key Points: 
  • These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
  • The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.
  • Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
  • Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR.

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on: 
Martedì, Ottobre 17, 2023
LILRB1, Merck Sharp & Dohme Federal Credit Union, Immuno-psychiatry, Pembrolizumab, Inflammation, Therapy, Merck & Co., Safety, ILT4, Cancer, LILRB2, Merck, HLA, KIR3DL1, ILT2, Patient, Pharmaceutical industry, MD

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points: 
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
  • ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
  • “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Retrieved on: 
Mercoledì, Ottobre 11, 2023
Partnership, Cancer, Engineering, Acquisition, Division, Multiple myeloma, Toxicity, CD34, University, University of Pittsburgh, Therapy, Immunology, CAR, Assistant, HLA, NK, Patient, Vaccine, Pharmaceutical industry

WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

Key Points: 
  • WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.
  • This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.
  • The addition of SNAP-CAR NK adds a third NK-focused technology to Coeptis' development portfolio.
  • "Expanding this agreement to include allogeneic NK cells enables our teams to develop cell therapies that can be developed with off-the-shelf convenience and greater access to patients.

Health Literacy Innovations (HLI) Offers Health Literacy Advisor (HLA) Software Discount in Honor of Health Literacy Month

Retrieved on: 
Martedì, Ottobre 3, 2023
Health literacy, Confusion, HLM, HLI, HLA, Sale, Management

BETHESDA, Md., Oct. 3, 2023 /PRNewswire-PRWeb/ -- In celebration of Health Literacy Month (October) Health Literacy Innovations (HLI), a leading health literacy company that creates tools to help eliminate medical mistakes and confusion due to low health literacy, today announces discounted prices on all NEW licenses.

Key Points: 
  • BETHESDA, Md., Oct. 3, 2023 /PRNewswire-PRWeb/ -- In celebration of Health Literacy Month (October) Health Literacy Innovations (HLI), a leading health literacy company that creates tools to help eliminate medical mistakes and confusion due to low health literacy, today announces discounted prices on all NEW licenses.
  • "Our vision is to create a health literate, jargon-free community for all health care consumers," says HLA Chief Content Expert and Multilingual Director Aracely Rosales.
  • HLI's Health Literacy Month sale ends October 31st.
  • "By availing more Health Literacy Advisor licenses and enhancing access to this tool, we are hoping to help more health communicators create plain language."

CHOP Researchers Improve Fitness of Cells Used in Cell Transplants

Retrieved on: 
Mercoledì, Settembre 27, 2023
Hematopoietic stem cell transplantation, University, Blood, CHOP, HLA, Culture, Genomics, Gene editing, Proteomics, Research, Cell, T32, Child, Doctor of Philosophy, HSCT, EVS, Transplant, Seminal vesicles, Flow cytometry, MD, Patient, Risk, DOI, Sickle cell disease, Mouse, Hospital, NIH, Hematopathology, Safety, Children's Hospital of Philadelphia, Vaccine, EV, HSPC

PHILADELPHIA, Sept. 27, 2023 /PRNewswire/ -- A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The study, published in the journal Blood, showed that targeting components in the cells called extracellular vesicles (EVs) relieves the stress on cells when outside of the body, improving their performance when they are transplanted back inside.

Key Points: 
  • Hematopoietic stem cell transplantation (HSCT) involves the transfer of HSPCs from a donor to patients with both benign and malignant diseases.
  • However, maintaining the fitness of these cells outside of the body poses a challenge, and any loss of fitness introduces the risk that the cells will not properly restore the blood and immune cell system in patients.
  • One process that we now learn contributes to cell equilibrium is the secretion of EVs, which are important for delivering messages from cell to cell and maintaining proper cell function.
  • "Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response," Blood, online Sept. 12, 2023, DOI: 10.1182/blood.2023022147